Group structure
7 companies in 4 countries
Loading your page…
Loading your page…
7 companies in 4 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
20 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACTIMMUNE1b 100ug/0.5ml · Vial | Interferon gamma | United States | Marketed | 1999 |
| BUPHENYL3gm/teaspoonful · Powder | Sodium phenylbutyrate | United States | Not marketed | 1996 |
| BUPHENYL500mg · Tablet | Sodium phenylbutyrate | United States | Not marketed | 1996 |
| DUEXIS26.6MG; 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Famotidine, Ibuprofen | United States | Not marketed | 2011 |
| Krystexxa8mg/50ml (0.16mg/ml) · Injection | Pegloticase | United States | Marketed | 2025 |
| KRYSTEXXA8MG · Injectable | Pegloticase | United States | Marketed | 2010 |
| PENNSAID1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Diclofenac | United States | Not marketed | 2009 |
| PROCYSBI25mg base | 75mg base · Capsule, delayed release | Mercaptamine | United States | Marketed | 2013 |
| PROCYSBI300mg base/packet | 75mg base/packet · Granule, delayed release | Mercaptamine | United States | Marketed | 2020 |
| RAVICTI1.1gm/ml · Liquid | Glycerol phenylbutyrate | United States | Marketed | 2013 |
| RAVICTI1.1 g / ml · Liquid | Glycerol phenylbutyrate | Canada | Marketed | 2016 |
| RAYOS1mg | 2mg | 5mg · Tablet, delayed release | Prednisone | United States | Not marketed | 2012 |
| TEPEZZA500mg · Injectable | Teprotumumab | United States | Marketed | 2020 |
| VIMOVO20MG BASE; 375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG BASE; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, delayed release | Esomeprazole, Naproxen | United States | Not marketed | 2010 |
| KYROBIL TAB32.4 mg / tab + 97.2 mg / tab · Tablet | Cascara sagrada, Phenolphthalein | Canada | Cancelled | 1974 |
| MGK0.025 mg / cap + 1 mg / cap + 75 mg / cap + 160 mg / cap · Capsule | Iodine, Iron, Magnesium, Potassium | Canada | Cancelled | |
| PHYTOMIN-C 500 TAB 500MG500 mg · Tablet | Ascorbic acid | Canada | Cancelled | 1979 |
| PHYTOPLEX TAB75 mg + 160 mg + 6 mg + 50 mg + 10 mg + 15 mg + .075 mg + 20 mg + 50 mg + 25 mg + 125 mg + 2 mg + 3 mg + 10000 unit + 5 mcg + 6 mg + 400 unit · Tablet | Ascorbic acid, Calcium, D-pantothenic acid, Choline, Dl-methionine, Inositol, Iodine, Iron, Magnesium, Nicotinamide, Phosphorus, Vitamin b6, Thiamine mononitrate, Vitamin a, Vitamin b12, Vitamin b2, Vitamin d | Canada | Cancelled | 1986 |
| TEPEZZA | Teprotumumab | Brazil | Cancelled | 2023 |
| Uplizna | Inebilizumab | Brazil | Cancelled | 2022 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 13 | 13 | 0 | CompaniesAll medicines |
| Canada | 5 | 1 | 4 | CompaniesAll medicines |
| Brazil | 2 | 0 | 2 | CompaniesAll medicines |
Also in the registers of United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.